- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03519243
Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis
Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
Study Overview
Detailed Description
The hypothesis of the study is that the efficacy of BCD-131 is equivalent to that of Mircera® based on the analysis of the primary endpoint (changes in the Hb level over the period of evaluation as compared to the baseline Hb level ) during the 21-week period of treatment.
This study is a study of the maintenance treatment of anemia. The study will include up to 100 dialysis patients with stage 5D chronic kidney disease, established efficacy of dialysis and renal anemia without other causes of anemia, receiving erythropoiesis-stimulating agents (ESA) and reaching target hemoglobin levels.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Minsk, Belarus
- City Clinical Hospital №9
-
-
-
-
-
St. Petersburg, Russian Federation, 194104
- City Mariin Hospital
-
St.Petersburg, Russian Federation
- B.Braun Avitum Russland Clinics Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent.
- Men and women aged from 18 to 75 years (inclusive) on the day of signing informed consent;
- End-stage kidney disease.
- Need for dialysis for at least 3 months before signing informed consent.
- Need for at least 12 hours on standard dialysis procedure weekly.
- rHuEpo (epoetin alpha, epoetin beta, darbepoetin alpha) administration for at least 3 months before signing informed consent.
- Regular rHuEpo (epoetin alfa, epoetin beta, darbepoetin alfa) administration 1, 2 or 3 times a week (stable dose, stable frequency) before signing informed consent.
- Target hemoglobin level (100-120 g/l) for at least 3 months before signing informed consent.
- Effective dialysis dose index (Kt/v) ≥1.2 for patients receiving hemodialysis and (Kt/v) ≥1.7 for patients receiving peritoneal dialysis.
- TSAT ≥20%, Serum ferritin >200 ng/ml.
- Patients and their sexual partners with childbearing potential must implement reliable contraceptive measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 4 weeks after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization. Reliable contraceptive measures include two methods of contraception, including one barrier method/
- Patients should be able to follow the Protocol procedures
Exclusion Criteria:
- Any other causes of anemia except for renal anemia, including folate and B12 deficiency, chronic blood loss, aluminium intoxication, sickle-cell anemia, chronic disease anemia (CRP above 20 mg/l), refractory anemia with blast cells in peripheral blood.
- Lupus nephritis of kidney disease due to systemic vasculitis.
- Platelet count below 100х10^9 cells/l.
- Scheduled kidney transplant during study participation period.
- Hypersensitivity to darbepoetin alfa or of any components of study drugs, or to Fe (III)-hydroxide-sucrose complex.
- Vaccination less than 8 weeks before signing informed consent.
- Liver cirrhosis with portal hypertension and/or splenomegaly and/or ascitis.
- HIV infection, active HBV, HCV.
- ALT, AST level above 3x ULN.
- Congestive heart failure (Grade IV NYHA)
- Resistant arterial hypertension.
- Unstable angina.
- Hemoglobinopathy, MDS, hematologic malignancy, PRCA.
- Severe secondary hyperparathyroidism.
- Gastrointestinal bleeding history.
- Thrombotic events history (myocardial infarction, stroke, TIA, DVT, PATE) less than 6 months before signing informed consent.
- Seizures, including epilepsy.
- Major surgery in less than 1 month before signing informed consent
- Blood transfusions in less than 3 months before signing informed consent.
- Acute inflammatory diseases or exacerbations of chronic inflammation.
- Severe psychiatric disorders and suicidal ideation and suicidal behavior.
- History of malignancy, excluding appropriately treated basal cell carcinoma or cervical carcinoma in situ.
- Alcohol or drug abuse.
- Simultaneous participation in other trials or in less than 3 months before signing informed consent
- Pregnancy of breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BCD-131 1,05 mcg/kg * conversion ratio
subcutaneously monthly
|
subcutaneously monthly
Other Names:
|
EXPERIMENTAL: BCD-131 1,7 mcg/kg * conversion ratio
subcutaneously monthly
|
subcutaneously monthly
Other Names:
|
EXPERIMENTAL: BCD-131 2,75 mcg/kg * conversion ratio
Subcutaneously monthly
|
subcutaneously monthly
Other Names:
|
ACTIVE_COMPARATOR: Mircera
subcutaneously monthly
|
subcutaneously monthly
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period
Time Frame: Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23
|
The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1.
The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.
|
Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131
Time Frame: Week 23
|
The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131 - the proportion of patients, in each group, who discontinued the study due to AEs/SAEs |
Week 23
|
The Proportion of BAb- and NAb-positive Patients
Time Frame: Week 9, 23
|
Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23. The immunogenicity endpoints will be analyzed after the completion of all periods of the study. |
Week 9, 23
|
AUC(0-672 Hour)
Time Frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
|
Area under the concentration curve from the moment of injection to 672 h [28 days])
|
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
|
AUC(0-∞)
Time Frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
|
Area under the concentration curve from the moment of injection to infinity
|
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
|
Cmax
Time Frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
|
Maximum serum concentration of the drug product) after the first injection of the test/reference drug
|
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
|
AUEC(0-672 Hour)
Time Frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
|
Area under the effect curve from the drug injection to 672 h [28 days]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug
|
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
|
AC-Emax
Time Frame: day 28
|
Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®
|
day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCD-131-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on BCD-131
-
Cellectar Biosciences, Inc.Active, not recruitingOsteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Pediatric Brain Tumor | DIPG | Pediatric Solid Tumor | Pediatric LymphomaUnited States, Australia, Canada
-
BiocadCompleted
-
BiocadCompleted
-
Cellectar Biosciences, Inc.National Cancer Institute (NCI)RecruitingHigh-Grade GliomaUnited States, Canada
-
Stealth BioTherapeutics Inc.ICON Clinical ResearchCompletedReperfusion Injury | STEMIUnited States, Hungary, Germany, Poland
-
Case Comprehensive Cancer CenterCompletedHead and Neck Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
University of Wisconsin, MadisonNational Institute of Dental and Craniofacial Research (NIDCR); Cellectar Biosciences...Active, not recruiting
-
Cellectar Biosciences, Inc.RecruitingMultiple Myeloma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Central Nervous System LymphomaUnited States, Australia, Czechia, Greece, Israel, Brazil, Finland, France, Spain, Turkey, United Kingdom
-
BiocadCompleted
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditionsUnited States